{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:50:42Z","timestamp":1769601042513,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.canrad.2017.09.003","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T19:55:37Z","timestamp":1519242937000},"page":"126-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Radiotherapy of relapse-refractory follicular lymphoma"],"prefix":"10.1016","volume":"22","author":[{"given":"\u00c9.","family":"Grignano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Deau-Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Loganadane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Breton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Burroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Bouscary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.M.","family":"Kirova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2017.09.003_bib0005","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2017.09.003_bib0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"89","author":"Illidge","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.09.003_bib0015","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood-2015-04-639336","article-title":"Risk-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma: analysis from a multicenter study","volume":"126","author":"Yang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2017.09.003_bib0020","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.canrad.2016.07.090","article-title":"[Radiotherapy in localized stages of follicular and diffuse non-Hodgkin's lymphomas]","volume":"20","author":"Demoor-Goldschmidt","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2017.09.003_bib0025","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1200\/JCO.2015.61.7654","article-title":"Treatment selection and survival outcomes in early-stage diffuse large b-cell lymphoma: do we still need consolidative radiotherapy?","volume":"33","author":"Vargo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2017.09.003_bib0030","doi-asserted-by":"crossref","first-page":"iii76","DOI":"10.1093\/annonc\/mdu200","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Dreyling","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2017.09.003_bib0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11864-015-0377-x","article-title":"Does radiation have a role in advanced stage Hodgkin's or non-Hodgkin lymphoma?","volume":"17","author":"Specht","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.canrad.2017.09.003_bib0040","doi-asserted-by":"crossref","first-page":"e781","DOI":"10.1016\/j.ijrobp.2010.10.013","article-title":"Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma","volume":"81","author":"Chan","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.09.003_bib0045","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0360-3016(01)01626-1","article-title":"A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment","volume":"51","author":"Girinsky","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.09.003_bib0050","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ijrobp.2010.12.062","article-title":"Low-dose radiotherapy in indolent lymphoma","volume":"81","author":"Rossier","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.09.003_bib0055","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijrobp.2004.06.210","article-title":"Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas","volume":"61","author":"Girinsky","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.09.003_bib0060","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ijrobp.2009.12.030","article-title":"External beam radiotherapy followed by 90Y ibritumomab tiuxetan in relapsed or refractory bulky follicular lymphoma","volume":"79","author":"Burdick","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.09.003_bib0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2017.09.003_bib0070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4Gy versus 24Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2017.09.003_bib0075","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.25117","article-title":"Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy","volume":"116","author":"Campbell","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2017.09.003_bib0080","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1269\/jrr.46.241","article-title":"Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells","volume":"46","author":"Skvortsova","year":"2005","journal-title":"J Radiat Res (Tokyo)"},{"key":"10.1016\/j.canrad.2017.09.003_bib0085","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.3109\/10428194.2014.990010","article-title":"Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?","volume":"56","author":"Janikova","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.canrad.2017.09.003_bib0090","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood.V120.21.1634.1634","article-title":"Treatment of early stage nodal follicular lymphoma using involved-field radiotherapy and rituximab: preliminary results of the Mir Trial (phase II study of the German Low Grade Lymphoma Study Group (GLSG))","volume":"120","author":"Herfarth","year":"2012","journal-title":"Blood"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818300052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818300052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:27:09Z","timestamp":1761136029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321818300052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1278321818300052"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2017.09.003","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy of relapse-refractory follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2017.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}